COMMUNIQUÉS West-GlobeNewswire

Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation
01/10/2026
Physician leaders share clinical insights on value-based therapy delivery, clinical trial access and integrated behavioral health in community oncology at major industry forums CERRITOS, Calif., Oct. 01, 2026 (GLOBE [...]
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/10/2026
NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve [...]
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/10/2026
CHARLESTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today [...]
Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
01/10/2026
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2027 on Thursday, October 29, 2026, [...]
Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026
01/10/2026
RADNOR, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in [...]
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/10/2026
WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly- [...]
Inspire Medical Systems, Inc. Announces Approval of New Hypoglossal Nerve Stimulation CPT® Codes by the AMA Editorial Panel
01/10/2026
MINNEAPOLIS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive [...]
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
01/10/2026
NEW HAVEN, Conn., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that novel [...]
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
01/10/2026
ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help eligible patients access TUDRIQEV in the U.S. now live WOBURN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Replimune Group [...]
Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche
01/10/2026
Subsidiary-Level Investment Provides Capital to Advance Commercialization of the Company’s Antiviral Intellectual Property Portfolio with No Issuance of MGRX Common Stock DALLAS, TEXAS, Oct. 01, 2026 (GLOBE NEWSWIRE [...]
Nutraville Introduces Pineal Guardian Advanced, a Liquid Botanical Formula Designed to Support Pineal Gland and Cognitive Wellness
01/10/2026
Tallmadge, OH, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nutraville is expanding its healthy-aging portfolio with Pineal Guardian Advanced, a liquid botanical formula that combines 11 nutritional and plant-based ingredients to [...]
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
01/10/2026
Please see enclosed pdf. Attachment 01102026_trading_in_shares_Coloplast_Fonden
Coloplast A/S - Major shareholder announcement
01/10/2026
Major shareholder announcement Reference is made to the press release issued by Coloplast A/S on 4 September 2026 regarding the expected implementation of the generational change in the ultimate ownership of Coloplast A [...]
IBA – TRANSPARENCY NOTIFICATION
01/10/2026
(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, October 1, 2026 06:00 PM Summary of the notification IBA (Ion Beam Applications), the world’s leading [...]
IBA SA – NOTIFICATION TRANSPARENCE
01/10/2026
(article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 1 octobre 2026, 18:00 Résumé de la notification IBA (Ion Beam Applications SA), le [...]
NMDP Gala Highlights Financial Challenges Facing Patients in Need of Blood Stem Cell Transplants
01/10/2026
Patient financial assistance requests are up 34% as NMDP and its supporters work to help more families overcome barriers to treatment MINNEAPOLIS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- With demand for financial assistance [...]
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
01/10/2026
LGSOC is a biologically distinct variant of ovarian cancer, with limited treatment options, that is generally less responsive to conventional chemotherapy Results presented in a late-breaking plenary session at IGCS [...]
FDA Grants Fast Track Designation for TRE-515 in Combination with KRAS G12C Inhibitors for the Treatment of Non-Small Cell Lung Cancer
01/10/2026
LOS ANGELES, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today that [...]
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
01/10/2026
In a predefined MRI substudy, trevogrumab prevented 70% of muscle loss associated with semaglutide treatment A pre-specified subgroup analysis found that patients meeting the low lean mass definition for sarcopenia had [...]

Pages